EdgarLookup

TENAX THERAPEUTICS, INC. — All Filings

925 total filings on record

Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.

Overview All Filings Financials Insiders
All 10-K 10-K/A 10-K405 10-KT 10-Q 10-Q/A 10KSB 10QSB 3 4 4/A 424B1 424B3 424B4 424B5 5 8-A12B 8-K 8-K/A ARS CERTNAS CORRESP CT ORDER D DEF 14A DEFA14A EFFECT FWP NT 10-K NT 10-Q NTN 10K POS AM PRE 14A PRER14A REGDEX REGDEX/A RW S-1 S-1/A S-1MEF S-2 S-3 S-3/A S-8 SC 13D SC 13D/A SC 13G SC 13G/A SCHEDULE 13D SCHEDULE 13G SCHEDULE 13G/A SEC STAFF LETTER UPLOAD
Form Description Accession Number Filed Period
4 PRIMARY DOCUMENT 0001654954-25-007737 Jul 3, 2025 Jul 1, 2025
4 PRIMARY DOCUMENT 0001654954-25-007738 Jul 3, 2025 Jul 1, 2025
SCHEDULE 13G 0001104659-25-064157 Jun 30, 2025
8-K FORM 8-K 0001654954-25-007104 Jun 17, 2025 Jun 11, 2025
4 PRIMARY DOCUMENT 0001654954-25-005949 May 20, 2025 May 16, 2025
4 PRIMARY DOCUMENT 0001654954-25-005950 May 20, 2025 May 16, 2025
SCHEDULE 13G 0000950170-25-072034 May 15, 2025
SCHEDULE 13G/A 0001415889-25-013260 May 15, 2025
10-Q 10-Q 0000950170-25-071395 May 14, 2025 Mar 31, 2025
8-K 8-K 0000950170-25-071382 May 14, 2025
SCHEDULE 13G/A 0001274173-25-000175 May 14, 2025
DEF 14A DEF 14A 0000950170-25-058329 Apr 25, 2025 Apr 24, 2025
DEFA14A DEFA14A 0000950170-25-058332 Apr 25, 2025
ARS ARS 0000950170-25-058333 Apr 25, 2025 Dec 31, 2024
424B3 FORM 424B3 0001654954-25-004572 Apr 23, 2025
EFFECT 9999999995-25-001213 Apr 23, 2025
CORRESP 0001654954-25-004482 Apr 21, 2025
UPLOAD 0000000000-25-004165 Apr 18, 2025
S-3 S-3 0001654954-25-004312 Apr 15, 2025
PRE 14A PRE 14A 0000950170-25-052503 Apr 9, 2025
SCHEDULE 13G/A 0001943462-25-000006 Apr 4, 2025
10-K 10-K 0000950170-25-044398 Mar 25, 2025 Dec 31, 2024
8-K 8-K 0000950170-25-044375 Mar 25, 2025
SCHEDULE 13G/A 0001079973-25-000408 Mar 18, 2025
4 PRIMARY DOCUMENT 0001943462-25-000004 Mar 12, 2025 Mar 5, 2025
8-K FORM 8-K 0001654954-25-002385 Mar 6, 2025 Mar 4, 2025
SCHEDULE 13G/A 0001274173-25-000095 Feb 14, 2025
SCHEDULE 13G/A 0001943462-25-000002 Jan 15, 2025
3 PRIMARY DOCUMENT 0001943462-25-000001 Jan 10, 2025 Jan 8, 2025
4 PRIMARY DOCUMENT 0001654954-24-015477 Dec 12, 2024 Dec 10, 2024
4 PRIMARY DOCUMENT 0001654954-24-015473 Dec 12, 2024 Dec 10, 2024
4 PRIMARY DOCUMENT 0001654954-24-015471 Dec 12, 2024 Dec 10, 2024
4 PRIMARY DOCUMENT 0001654954-24-015472 Dec 12, 2024 Dec 10, 2024
4 PRIMARY DOCUMENT 0001654954-24-015474 Dec 12, 2024 Dec 10, 2024
4 PRIMARY DOCUMENT 0001654954-24-015475 Dec 12, 2024 Dec 10, 2024
4 PRIMARY DOCUMENT 0001654954-24-015476 Dec 12, 2024 Dec 10, 2024
3 PRIMARY DOCUMENT 0001654954-24-015251 Dec 6, 2024 Dec 2, 2024
SCHEDULE 13G 0001943462-24-000006 Dec 5, 2024
8-K FORM 8-K 0001654954-24-015161 Dec 4, 2024 Dec 2, 2024
S-8 FORM S-8 0001654954-24-014917 Nov 26, 2024
SC 13G/A JANUS AMENDMENT 0001274173-24-000120 Nov 14, 2024
SC 13G/A SC 13G/A 0001104659-24-118640 Nov 14, 2024
SC 13G 0000929638-24-003915 Nov 14, 2024
10-Q FORM 10-Q 0001654954-24-014262 Nov 13, 2024 Sep 30, 2024
SC 13G/A 0000935836-24-000669 Nov 13, 2024
8-K FORM 8-K 0001654954-24-014203 Nov 13, 2024
SC 13G TENAX THERAPEUTICS, INC. 0000902664-24-006402 Nov 12, 2024
8-K FORM 8-K 0001654954-24-013505 Oct 30, 2024 Oct 25, 2024
DEF 14A DEF 14A 0001654954-24-012375 Sep 27, 2024 Oct 25, 2024
424B3 FORM 424B3 0001654954-24-011845 Sep 12, 2024